NewAmsterdam Pharma Shares Surge 98% After Going Public Via SPAC


Shares of NewAmsterdam Pharma Co. N.V. surged 98% to $19.56 after it made its public debut via combining with a SPAC.
The clinical-stage company said that it closed its business combination with Frazier Lifesciences Acquisition Corp. NewAmsterdam shares began trading on the Nasdaq Capital Market Wednesday morning under the ticker NAMS.

Read more on Market Watch…

Shanda Consult has been working with SPACs for many years, and our network of SPAC executives has deep experience in the sector. If you need to learn more about how to successfully use a SPAC structure and perhaps wish to set up your own SPAC, we are here to help.

Please contact us with any questions you may have.